Compare Gilead Sciences, Inc. (GILD) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Utilities Select Sector SPDR Fund — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Utilities Select Sector SPDR Fund trades at $43.64. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Utilities Select Sector SPDR Fund pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| GILD | XLU | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | — |
52-Week High | $155.80 | $47.73 |
52-Week Low | $110.56 | $41.31 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLU trades at $43.61, up 0.51% with a bearish technical signal from moving averages. The ETF benefits from AI-driven power demand, with recent news highlighting increased call option activity and sector momentum. Support sits at $42-43 while resistance is at $44-45. The utilities sector is gaining attention as AI data centers drive electricity consumption growth.
The outlook remains mixed with technical weakness offset by strong sector fundamentals. AI power demand creates growth opportunities, but regulatory risks and interest rate sensitivity pose challenges. The ETF's defensive income characteristics provide stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
